Martin Shkreli

	A	B	C
1	Main
2		Brand	Remsima
3		Generic	infliximab
4		Indication	RA
5		Competition	54% market share in EU, 20% for JNJ, 25% for two biosimilars
6			32% market share in US vs 53% for JNJ, 15% for two biosimilars